Directory of Pharma Companies and News
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofiâ€™s programs in oncology and immunology.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|2018-02-08||Sanofi announces new safety data for investigational avalglucosidase alfa in patients with Pompe disease|
|2018-01-31||Sanofi Genzyme highlights rare disease data at WORLDSymposium 2018|
|2018-01-08||Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs|
|2018-01-07||Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance|
|2017-12-18||Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the tre...|
|2017-12-15||FDA lifts clinical hold on fitusiran|
|2017-12-13||Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamo...|
|2017-12-07||Sanofi explores combination treatments for multiple myeloma in new late-stage trials|
|2017-11-09||Sanofi, Principia agree to develop multiple sclerosis drug candidate|
|2017-11-02||Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditar...|